跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ENERZAIR BREEZHALER - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ENERZAIR BREEZHALER
Authorized
STANDARD
ENERZAIR BREEZHALER
novartis pharmaceuticals canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
4c44e5101b80b695
Company
novartis pharmaceuticals canada inc
Type
Standard
Approval Details
Approval Id
4c44e5101b80b695
Drug Approval Canada Name
ENERZAIR BREEZHALER
Product Name
ENERZAIR BREEZHALER
Status
Marketed
Status Date
2020-11-05
Original Market Date
2020-11-05
Din
02501244
Drug Class
Human
Dosage Form
Capsule
Route Of Administration
Inhalation
Schedule
Prescription
Ahfs
12:12.08.12
Atc Original
R03AL12 INDACATEROL, GLYCOPYRRONIUM BROMIDE AND MOMETASONE
Atc Name
r 03 al 12
Aig Number
0362336001
Company Name
novartis pharmaceuticals canada inc
Company Address
100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1
Active Ingredients
MOMETASONE FUROATE
160 MCG
INDACATEROL (INDACATEROL ACETATE)
150 MCG
GLYCOPYRRONIUM (GLYCOPYRROLATE)
50 MCG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
4c44e5101b80b695
Type
Standard
Back to Health Canada Approvals